Citadel Advisors’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Citadel Advisors’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-141,226	Closed	-$36K	–	14122
2022 Q2	$36K	Buy	+141,226	New	+$48.6K	﹤0.01%	12133
2022 Q1	–	Sell	-16,213	Closed	-$13K	–	15100
2021 Q4	$13K	Buy	+16,213	New	+$16.9K	﹤0.01%	13652
2021 Q2	–	Sell	-112,439	Closed	-$177K	–	14753
2021 Q1	$177K	Buy	112,439 +78,804	+234%	+$135K	﹤0.01%	11853
2020 Q4	$50K	Buy	33,635 +21,446	+176%	+$30.1K	﹤0.01%	10567
2020 Q3	$16K	Buy	+12,189	New	+$20.9K	﹤0.01%	9901

Other funds holding MITO

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's MITO Position: Q3 2022 in Review

Citadel Advisors sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q3 2022, closing a stake of 141,226 shares — an estimated $36K sold.

Citadel Advisors first reported a position in MITO in Q3 2020 and held it in 5 quarters. The position peaked at $177K in Q1 2021. 12 funds tracked by Wall St. Rank hold MITO as of Q3 2022.

Citadel Advisors reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 141,226 Stealth BioTherapeutics Corp. ADS shares in Q3 2022, an estimated $36K.
Citadel Advisors first reported a position in Stealth BioTherapeutics Corp. ADS in Q3 2020 and held it in 5 quarters.
Citadel Advisors's Stealth BioTherapeutics Corp. ADS position peaked at $177K in Q1 2021.
12 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.